Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 14/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.44 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800495 | 0.86 | POLB (0.34) | HCRTR2HCRTR1 | |
| SCHEMBL3412360 | 0.85 | HCRTR2 (0.41) | HCRTR2HCRTR1GRM5 | |
| SCHEMBL3417284 | 0.85 | HCRTR2 (0.41) | HCRTR2HCRTR1GRM5 | |
| SCHEMBL3417285 | 0.85 | HCRTR2 (0.41) | HCRTR2HCRTR1GRM5 | |
| SCHEMBL3411958 | 0.85 | HCRTR2 (0.41) | HCRTR2HCRTR1GRM5 | |
| SCHEMBL1341088 | 0.84 | HCRTR2 (0.44) | HCRTR2HCRTR1GRM5 | |
| SCHEMBL1340420 | 0.84 | HCRTR2 (0.44) | HCRTR2HCRTR1GRM5 | |
| SCHEMBL3417288 | 0.84 | HCRTR2 (0.44) | HCRTR2HCRTR1GRM5 | |
| SCHEMBL2799399 | 0.84 | HCRTR1 (0.42) | HCRTR2HCRTR1HHATGRM5HTT | |
| SCHEMBL3416042 | 0.80 | PTGS1 (0.37) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | HCRTR2 2/4885HCRTR1 1/4885HHAT 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.